Ross\Johnson & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ross\Johnson & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241	Buy	+1	New	+$219	﹤0.01%	209

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ross\Johnson & Associates's JAZZ Position: Q2 2026 in Review

Ross\Johnson & Associates opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 1 share worth $241. The stake represents ﹤0.01% of the portfolio and ranks #209 among its holdings.

641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Ross\Johnson & Associates held 1 share of Jazz Pharmaceuticals worth $241 as of Q2 2026.
Jazz Pharmaceuticals was a new Ross\Johnson & Associates position in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #209 holding.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.